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Abstract
Background: A number of data indicate that the lectin pathway of complement activation contributes to the
pathophysiology of ischemic stroke. The lectin pathway may be triggered by the binding of mannose-binding
lectin (MBL), ficolin-2 or ficolin-3 to different ligands. Although several papers demonstrated the significance of
MBL in ischemic stroke, the role of ficolins has not been examined.
Methods: Sera were obtained within 12 hours after the onset of ischemic stroke (admission samples) and 3-4 days
later (follow-up samples) from 65 patients. The control group comprised 100 healthy individuals and 135 patients
with significant carotid stenosis (patient controls). The concentrations of ficolin-2 and ficolin-3, initiator molecules of
the lectin complement pathway, were measured by ELISA methods. Concentration of C-reactive protein (CRP) was
also determined by a particle-enhanced immunturbidimetric assay.
Results: Concentrations of both ficolin-2 and ficolin-3 were significantly (p < 0.001) decreased in both the
admission and in the follow-up samples of patients with definite ischemic stroke as compared to healthy subjects.
Concentrations of ficolin-2 and ficolin-3 were even higher in patient controls than in healthy subjects, indicating
that the decreased levels in sera during the acute phase of stroke are related to the acute ischemic event. Ficolin-3
levels in the follow-up samples inversely correlated with the severity of stroke indicated by NIH scale on admission.
In follow-up samples an inverse correlation was observed between ficolin-3 levels and concentration of S100b,a n
indicator of the size of cerebral infarct. Patients with low ficolin-3 levels and high CRP levels in the follow up
samples had a significantly worse outcome (adjusted ORs 5.6 and 3.9, respectively) as measured by the modified
Rankin scale compared to patients with higher ficolin-3 and lower CRP concentrations. High CRP concentrations
were similarly predictive for worse outcome, and the effects of low ficolin-3 and high CRP were independent.
Conclusions: Our findings indicate that ficolin-mediated lectin pathways of complement activation contribute to
the pathogenesis of ischemic stroke and may be additive to complement-independent inflammatory processes.
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Background
Neuroinflammation is a key element in the ischemic
cascade after cerebral ischemia that results in cell
damage and death in the subacute phase.[1]
Complement activation is one of the pathological
mechanisms that contribute to the ischemic/reperfusion
injury in ischemic stroke [2-4]. Among other neuroin-
flammatory processes, the complement system is also
activated during tissue injury and has recently been con-
sidered as a new potential therapeutic target in ischemic
stroke [5] and in intracerebral haemorrhage [6]. Both
animal experiments and observations made in stroke
patients indicate that activation of the complement sys-
tem is one of the mechanisms contributing to the exten-
sion of the cerebral infarct after ischemic stroke [7].
Several studies have demonstrated the essential role of
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bral ischemia. Such evidence includes (i) an increased
expression of complement proteins and complement
receptors after permanent middle cerebral artery occlu-
sion (MCAO) [8-11] (ii) different pathological events in
complement-deficient/-sufficient animals after the onset
of cerebral ischemia compared to wild-type littermates:
complement deficient animals are at least partially pro-
tected after transient MCAO [12-15]. (iii) In rodent
experimental models, complement depletion induced
using the cobra venom factor (CVF) [16,17], as well as
complement inhibition by a plasma-derived C1-inhibitor
[18,19], a recombinant C1 inhibitor [20], CR2-Crry [13]
and intravenous immunoglobulin administration [14]
were proven to exert beneficial, neuroprotective effects,
indicating the protective role of complement antagonism
and inhibition.
Only a few studies have explored complement activa-
tion in patients with ischemic stroke [21,22]. Recently,
we found that sC5b-9 levels determined at admission
exhibited a significant positive correlation with the
clinical severity of stroke, as well as with the extent of
the neurological deficit as determined by different
scales [3]. Our findings suggested that the lectin path-
way is primarily responsible for the activation of com-
plement in ischemic stroke. In agreement with these
findings, Cervera et al. [4] demonstrated both in mice
and stroke patients that genetically determined MBL-
deficiency is associated with a better outcome after
a c u t ei s c h e m i cs t r o k e .I nah i g hn u m b e ro fp a t i e n t s
with ischemic stroke, Osthoff et al. [23] found that a
deficiency of the mannose-binding lectin is associated
with smaller infarction size and a more favorable out-
come. More recently, the group of De Simoni [24]
reported on the formation of functional MBL/MASP-2
complexes in plasma in mice after MCAO, and
demonstrated that molecules, which strongly bound to
MBL, induced significant reduction in neurological
deficits and infarct volume, when administered 6 h
after transient MCAO. These data support the notion
that the lectin pathway plays a crucial role in the
development of ischemic stroke.
Apart from MBL, the ficolins also serve as recognition
molecules in the lectin complement pathway. Three dif-
ferent ficolins have been described in humans. Ficolin-1,
-2, and -3 are derived from the genes FCN1, FCN2,a n d
FCN3, respectively. In healthy individuals, ficolin-2 and
-3 are present in the serum and plasma in relatively
high concentrations, while the concentration of ficolin-1
is much lower [25]. Similar to MBL, the ficolins are
associated with a set of three serine proteases, termed
MBL-associated serine proteases (MASPs), enabling acti-
vation of the complement system. The primary activator
of the lectin pathway appears to be MASP-2.
As described above, there are abundant data about the
significance of MBL in ischemic stroke. The role of the
ficolins, initiator molecules of the lectin complement
pathway, however, has never been studied in this dis-
ease. Therefore, we measured the levels of ficolin-2 and
ficolin-3 in sera from 65 patients with ischemic stroke
and from controls. In order to assess the clinical signifi-
cance of the results, serum concentrations of these pro-
teins were correlated to an indirect measure of the
stroke severity (NIHss), S100b concentration on day 3,
which is an indicator of the size of cerebral infarct,
[26,27] as well as the outcome of the disease expressed
by the modified Rankin scale.
Besides complement activation, other inflammatory
processes are also known to contribute to the pathogen-
esis of the ischemic stroke [1]. Among them, CRP-asso-
ciated processes were mostly studied. In 2005, Di Napoli
et al [28] summarized evidence for CRP as an indepen-
dent predictor of cerebrovascular events in at-risk indi-
v i d u a l sa n di t su s e f u l n e s si ne valuating prognosis after
stroke. It was also demonstrated that C-reactive protein
predicts the prognosis of patients with functional dis-
ability after the first occurrence of ischemic stroke [29]
and correlates to the infarct volume [30]. Recently,
Ormstad et al. [31] provided evidence that CRP plays an
important role in the progression of cerebral tissue
injury. In addition, in our previous study [3] we found
that complement activation and elevated CRP levels
were independently associated with the clinical severity
and different outcome measures of ischemic stroke,
indicating their additive effect. Therefore, serum con-
centrations of CRP and its relationship to the ficolin
levels were also examined here.
Methods
Patients and control subjects
Patients with ischemic stroke included in the present
work were admitted to two centers: the Department of
Neurology, University of Pecs,H u n g a r y( 3 9p a t i e n t s : 2 0
men and 19 women, aged 49-84 years) and the Depart-
ment of Neurology, Kútvölgyi Clinical Centre, Semmel-
weis University, Budapest, Hungary (26 patients:10 men
and 16 women, aged 58-87 years) (Table 1). The man-
agement of ischemic stroke was in accordance with the
guidelines of the Stroke Council of the American Heart
Association/American Stroke Association [32] None of
the patients were treated by intravenous thrombolysis.
Patients with stroke were enrolled upon the first occur-
rence of acute ischemic stroke only; all patients had
neuroimaging (most of them brain MRI, but at least cra-
nial CT). No patients had hemorrhagic infarction. All
patients with definite acute clinical symptoms were
enrolled regardless of etiology i.e. lacunar or territorial
infarct caused by thrombosis or emboli. Exclusion
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stroke, an elevated WBC, erythrocyte sedimentation rate
(ESR), high-sensitivity CRP (hsCRP, cut-off value < 10
mg/L), procalcitonin on admission (cut-off value < 0.05
ng/mL), positive chest X-ray, hemorrhagic stroke
defined by an acute cranial CT scan, and those who
declined to participate in the study. Almost all patients
had hypertension and elevated cholesterol/triglyceride
levels. All patients were therefore treated for such risk
factors; nevertheless the effect of such treatments on the
ficolin pathway is unlikely. An evidence-based guideline
[33] was followed to detect post-stroke infectious com-
plications (in short, physical and laboratory measures
i n c l u d i n gW B C ,E S R ,h s C R P ,P C T ,f e v e r ,a b n o r m a l
urine, chest X-ray or positive cultures). Such complica-
tions occurred on the 4
th day as an average, and were
located to the respiratory system and urinary tract even
in the absence of catheterization; in addition, throm-
bophlebitis occurred in a single case.
A tt h et i m eo fa d m i s s i o n ,s e v e r i t yo fs t r o k ew a s
assessed using the National Institutes of Health Stroke
Scale (NIHSS) [34]. Blood samples were obtained at the
time of admission (admission samples: the median time
from the onset of symptoms was 7 hours in the Buda-
pest cohort and 8.5 hours in the Pecs cohort), and 72 to
96 hours later (follow-up samples). Five and four
patients in the Pecs and Budapest cohorts, respectively,
developed infections. The outcome of disease was
assessed with the modified Rankin scale [35].
Serum samples were also taken from 100 healthy
volunteers as controls (Table 1). Additionally, 134
patients with significant carotid atherosclerosis served as
controls (Table 1). In agreement with international
guidelines, significant carotid atherosclerosis was defined
as 70-100% stenosis of the carotid artery determined by
Duplex scan sonography. The examination was indicated
in the case of other vascular disorders or risk factors of
vascular disorders. None of the patients had definite
residual signs and no symptoms suggesting acute ische-
mia. Some of these patients had either peripheral arter-
ial disease or coronary disease, and in these patients
carotid Duplex scans were performed to detect asympto-
matic severe carotid stenosis (as a common comorbid-
ity). Some of the patients had non-specific symptoms (i.
e. dizziness) or transient ischemic attack previously; in
these patients diagnostic carotid Duplex scans were per-
formed. Lacunar strokes defined by neuroimaging were
no exclusion criteria.
Serum samples of the patients and of the controls
were stored at -80°C in the Hungarian laboratories until
transported on dry ice to Copenhagen.
The study was approved by the local ethics commit-
tees, and all patients and control subjects gave informed
consent.
Laboratory methods
The serum concentrations of the proteins ficolin-2 [36]
and ficolin-3 [37] were determined by ELISA-based
methods at the Laboratory of Molecular Medicine,
Department of Clinical Immunology, Rigshospitalet,
Copenhagen, Denmark. Briefly, microtiter plates were
coated with either monoclonal anti-ficolin-2 antibody
(FCN216) or monoclonal anti-ficolin-3 antibody
(FCN334) in phosphate buffered saline (PBS) overnight
at 4°C. Samples diluted 1:50 or 1:640 in sample buffer
(PBS-T with 1% mouse serum and bovine serum) were
added in triplets to washed wells and incubated for 3
hours at 37°C. Ficolin-2 was detected with biotinylated
monoclonal anti-ficolin-2 antibody (FCN219) and fico-
lin-3 was detected with biotinylated monoclonal anti-
ficolin-3 antibody (FCN334) by incubation overnight at
4°C. Washed wells were incubated for 1 hour at 37°C
with HRP-conjugated streptavidin. Plates were devel-
oped for 15 min with OPD (o-phenylenediamine) sub-
strate solution and stopped by adding 1M H2SO4.T h e
optical density was measured at 490 nm. A standard
Table 1 Main characteristics of the cohorts tested




Patients with severe athero-sclerosis
(patient controls)
Number of subjects 65 100 134
Sex, males/females 20/19 47/53 88/46
Age, years, mean ± S.D. 69.8 ± 9.8 35.5 ± 9 69.8 ± 9.9




Lethal outcome yes/no 7/58
NIH scale at admission, ≥ 16 vs < 16 58/7
Serum S100b levels, pg/ml, median (IQ range) 0,27 (0.12-0.93)
Outcome: modified Rankin scale at discharge: 0/1/2/3/4/5/6 4/13/14/7/9/7/1
*in the Pécs and Budapest groups, respectively.
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each assay as were a sample control. The lower limit of
detection in these assays is 5 ng/ml of ficolin-2 and 1
ng/ml of ficolin-3. The inter-assay coefficient of varia-
tion (CV) is 7.1% and 4.7% and the intra-assay CV 4.3%
and 3.9% for the ficolin-2 and ficolin-3 assay,
respectively.
Human S100b concentrations were measured by an
ELISA method (BioVendor, Modrice, Czech Republic).
In our previous study, we found that the concentration
of S100b was the highest 72 hours after the onset of
stroke, therefore concentration was determined at this
timepoint [27].
Serum CRP concentrations were measured by particle-
enhanced immunturbidimetric assay, using an auto-
mated laboratory analyzer (Roche Cobas Integra 400,
Basel, Switzerland).
Statistical evaluation of the results
Statistical analysis was performed using the GraphPad
Prism 3.0 (GraphPad Software Inc, San Diego, CA,
http://www.graphpad.com) and SPSS 13.0 (SPSS Inc.,
Chicago, IL) software. Between-group differences were
evaluated by the Mann-Whitney test. Correlations
between the variables were expressed using non-para-
metric Spearman’s correlation coefficients. The categori-
cal variables were compared with the c
2 test for trend.
The association between the serum concentration of
selected proteins and the outcome of stroke was calcu-
lated by multiple logistic regression, adjusted for the sex
and the age of the patients. All tests were two-tailed. All
data are presented as median values with the 25
th to
75
th percentiles in parentheses unless stated otherwise.
Results
The concentrations of the proteins of the lectin pathway
and CRP in the sera of patients with ischemic stroke, as
compared to healthy controls and patient controls
The serum levels of ficolin-2, ficolin-3 and CRP were
measured in the samples obtained from 65 stroke
patients on admission and 3-4 days later (follow-up
samples), as well as in the sera of 100 healthy volunteers
and 134 patient controls (patients with severe carotid
atherosclerosis without acute stroke) (Figure 1). Com-
pared to both healthy controls and patient controls,
both ficolin-2 ficolin-3 levels were significantly lower
both in the admission and follow-up sera of stroke
patients. When all patients were considered, CRP levels
were significantly higher in the admission samples than
in the sera of healthy controls but were nearly equal to
that measured in the sera of patient controls. By con-
trast in the follow up samples, CRP levels were signifi-
cantly higher as compared to both control groups.
When patients who developed infections were not
considered, the difference between stroke patients and
controls became non-significant (data not shown). As
for the two controls groups, all the three variables had
significantly higher concentration in the sera of patient
controls than in the healthy controls, although the dif-
ference in the ficolin-3 levels was small.
Follow-up ficolin-3 levels correlated with the indirect
measures of stroke severity and infarct size
Ficolin-3 concentrations measured in the follow-up sam-
ples but not in the admission samples exhibited a signif-
icant, negative correlation with indirect measures of
stroke severity i.e. the NIH score determined on admis-
sion (Figure 2, panel A). Patients were divided into two
groups in a similar manner to Foerch 2005 [26]; those
with a NIH scale of < 16 with relatively good expected
outcome and those with NIH scale of ≥ 16 with poor
expected outcome, and the ficolin-3 levels were com-
pared accordingly. There were significantly (p = 0.017)
lower ficolin-3 levels in the former than in the latter
group. By contrast, no significant differences in the fico-
lin-2 levels (p = 0.309) were found between the two
groups (data not shown).
In addition, we found significant negative correlation
between ficolin-3 concentrations and the S100b level
measured in the follow-up samples but not in the
admission samples (Figure 2, panel B). The levels of
ficolin-2 did not correlate with the S10B concentrations
(data not shown).
CRP concentrations in follow-up samples were signifi-
cantly higher in patients with high (≥ 16) NIH score
(Figure 2, Panel C) ,b u td i dn o ts i g n i f i c a n t l yc o r r e l a t e
with the S100b levels (Figure 2, panel D).
Ficolin-3 and CRP levels in follow-up samples correlate
with the outcome of acute ischemic stroke
The levels of the ficolins and CRP were related to the
outcome of the disease, as assessed by the modified
Rankin scale (Figure 3). When patients were divided
according to unfavorable (3 to 6) and favorable (0 to 2)
modified Rankin scores, ficolin-3 levels were lower in
the former group, supporting the association with an
unfavorable outcome. The difference was significant
only in the follow-up samples, while almost significant
in the admission samples (Figure 3, panels A and B).
When the 9 patients, who developed infectious compli-
cations were excluded, CRP levels both in admission
and follow up samples were significantly higher in the
patient group with unfavorable compared to favorable
outcome (Figure 3, panels C and D).
We confirmed these data by performing a multiple
logistic regression analysis. Unfavorable (modified Ran-
kin scale 3 to 6) vs. favorable (modified Rankin scale 0
to 2) outcome was regarded as a dependent variable,
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considered as independent variables (Table 2). Since
both ficolin-3 and CRP levels were included in the ana-
lysis, those 9 patients who developed infectious compli-
cations were excluded.
Both ficolin-3 and CRP levels measured in the follow
up samples were significantly associated with the out-
come of the disease: lower ficolin-3 and higher CRP
values were found in the unfavorable compared to the
favorable outcome group. Similar but only, marginally
significant (ficolin-3) or weakly significant (CRP) asso-
ciations were found when the admission samples were
analyzed.
Next, in order to assess the strength of association
between the low ficolin-3 and high CRP levels on the
one hand and the unfavorable outcome of the disease
on the other hand, we repeated the analysis as above in
the follow-up samples by including ficolin-3 and CRP
levels as low/high values. Ficolin-3 levels below or equal
to the median (16 μg/ml for both the admission and fol-
low up samples) were considered low, while those above
the median value were considered high. CRP levels
above median (7.7 mg/L) were considered high (Table
3). In the analysis, adjusted for sex and age of the
patients, both the low ficolin-3 and the high CRP levels
significantly predicted an unfavorable outcome, with
odds ratios of 5.6 and 3.9, respectively.
Correlation between the baseline NIH score, serum S100b
concentration in the follow up samples as well as the
outcome of the disease
Finally, we assessed the relationship between the base-
line NIH scale as an indirect measure of the severity of
the stroke, the concentration of the S100b in the follow
up samples as an indicator of the infarct size, and the
outcome of the disease assessed by the modified Rankin
scale (Figure 4). Both measures exhibited highly signifi-
cant correlation to the outcome: patients with high
Figure 1 Concentrations of ficolin-2, ficolin-3 and C-reactive protein in the sera of patients with acute ischemic stroke. Concentrations
at the time of hospital admission and on day 3, as compared to healthy controls (HC) and patient controls (PC, patients with > 70% stenosis of
the carotid artery without acute stroke) are shown. P values (* < 0.05, *** < 0.01) for the non-parametric Kruskal-Wallis test followed by the Dunn
post hoc test are indicated.
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those with low NIH scale, and patients with unfavorable
outcome had higher serum S100b concentrations at 72
hours than those with a favorable outcome.
Discussion
We report here on three novel observations: (i) the
decrease of serum concentrations of two proteins of the
lectin pathway during the acute phase of ischemic
stroke; (ii) an inverse correlation of ficolin-3 levels
obtained 3-4 days post-admission with the severity and
outcome of acute ischemic stroke; (iii) the independent
effect of low ficolin-3 and high CRP levels on the out-
come of the disease.
As compared to healthy subjects, the serum concen-
trations of both ficolin-2 and ficolin-3, initiator proteins
of the lectin complement pathway, were significantly
lower in the samples taken from patients with ischemic
stroke immediately after admission (i.e. within hours
after the onset of the symptoms). The levels of these
proteins did not further change during the initial 3-4
days of stroke. The differences observed between stroke
patients and healthy individuals seem to be valid, since
the ficolin-2 and ficolin-3 concentrations measured in
the sera of healthy subjects are similar to previously
reported data [38]. In addition, ficolin-2 and ficolin-3
levels were significantly lower in sera of patients with
definite stroke compared to patients with severe carotid
Figure 2 Correlation between ficolin-3 levels with severity and outcome of stroke and size of infarct. Panel A: Negative correlation
between serum ficolin-3 levels in follow-up (FU) samples and the severity of stroke as assessed by the NIH stroke scale at admission in 65
patients with ischemic stroke. Patients with unfavorable (≥ 16) vs. favorable (< 16) NIH scale were compared. P value of Mann-Whitney test is
indicated. Panel B: Negative correlation between serum ficolin-3 levels in follow-up samples and the size of cerebral infarct as assessed by the
S100b level in follow-up samples. Spearman’s correlation coefficient and its significance is indicated. Panel C: Positive correlation between serum
CRP levels in follow-up samples and the severity of stroke as assessed by the NIH scale at admission in 65 patients with ischemic stroke. Patients
with unfavorable (≥ 16) vs. favorable (< 16) NIH scale were compared. P value of Mann-Whitney test is indicated. Panel D: No significant
correlation between serum CRP levels in follow-up samples and the size of cerebral infarct as assessed by the S100b level in follow-up samples.
Spearman’s correlation coefficient and its significance is indicated.
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age of this group was equal to that of stroke patients.
This control group of patients exhibited even higher
ficolin levels than healthy subjects. These data may sug-
gest that the decreased levels of ficolins in the acute
Figure 3 Relationship of serum ficolin-3 and CRP levels with outcome. Differences in ficolin 3 (left panels, A, C) and CRP (right panels, B, D)
levels measured in admission samples (upper panels, A, B) and in follow-up samples (lower panel, C, D) comparing patients with a favorable
(modified Rankin scale: 1 or 2) and an unfavorable (modified Rankin scale 3 to 6) outcome. In the case of the CRP calculations, nine patients
with infectious complications were excluded from the analysis. The significance of the Mann-Whitney test is indicated.
Table 2 Relationship between the ficolin-3 and CRP levels
and unfavorable (modified Rankin scale 3 to 6) vs.
favorable (modified Rankin scale: 1 to 2) outcome of
ischemic stroke as calculated by multiple logistic
regression analysis
OR (95% CI) (p value)**
Admission samples Follow-up samples
















Multiple logistic regression analysis adjusted for sex and age was used. Nine
patients with infectious complications were excluded from the analysis.
Table 3 Relationship between the low ficolin-3 and high
CRP levels and outcome of ischemic stroke
OR*** (95% CI) P value
Low vs. high ficolin 3* 5.628 (1.497-21.153) 0.044
High vs. low CRP** 3.949 (1.036-15.055) 0.011
Sex (females/males) 1.171 (0.306-4.491) 0.818
Age, years 1.041 (0.966-1.122) 0.294
*low ficolin 3 defined as < 16 μg/ml (median), **high CRP levels defined as >
7,7 mg/L (median), ***unfavorable (modified Rankin scale: 3 to 6) vs. favorable
(modified Rankin scale: 0 to 2) outcome. Multiple logistic regression analysis
adjusted to sex and age was used.
Nine patients with infectious complications were excluded from the analysis.
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severe atherosclerosis, but rather a decrease in ficolin-2
and ficolin-3 concentrations may happen in the very
early phase of the acute ischemic event. In addition,
these data indicated that the difference in ficolin con-
centrations comparing healthy controls and stroke
patients were not related to the difference between their
ages.,.
The decreased concentration of ficolins could be
observed in the very early phase of ischemic stroke and
remained unchanged during the next 3-4 days. It seems
reasonable to surmise that this decrease was due to con-
sumption through the binding of the molecules to the
apoptotic and necrotic cells in the penumbra of the cer-
ebral infarct [2]. Moreover, ficolin-2 and ficolin-3 have
also been shown to be involved in the sequestration of
dying host cells [39]. The observations made by Wang
et al. [40] are of particular interest, since these authors
reported that maternal plasma concentrations of ficolin-
3 and ficolin-2 were significantly (p < 0.001) lower in
preeclamptic pregnancies than in uncomplicated preg-
nancies, due to the sequestration of the proteins in pla-
centa. Additionally, they found that both ficolins but
particularly ficolin-3 were associated with ischemic pla-
centa tissue.
According to our second observation, lower level of
ficolin-3 in the follow-up samples were associated with
greater size of the cerebral infarct indicated by higher
S100b levels in the sera. Astrocyte-derived S100b con-
centration is a marker of the degree and the severity of
cellular injury in acute ischemic stroke [41]. The exami-
nation of S100b protein has been accepted as a good
biomarker of the infarct size [26,42-44]. The concentra-
tion of S100b is known to be the highest 72 hours after
the onset of stroke [27].
In addition, ficolin-3 levels inversely correlated with
the indirect measure of the severity of ischemic stroke, i.
e. with the NIHSS neurological deficit score. Higher
NIHSS scores define more severe deficits [34].
Additionally, a strong negative correlation was found
between ficolin-3 concentration and the outcome of the
disease measured with modified Rankin scale. This
negative correlation indicates that low ficolin-3 levels
are associated with an unfavorable prognosis. This asso-
ciation is most probably secondary to the negative cor-
relation between ficolin-3 on the one hand and the
severity of ischemic stroke and the infarct size on the
other hand, as discussed above. It is well known that
both the high baseline NIHSS score and the high serum
S100b levels predict poor prognosis of ischemic stroke,
which was also found in the present study (Figure 4).
The lack of clinical correlates of ficolin-2 could be
explained by the observation that ficolin-3 has the high-
est concentration and the greatest complement-activat-
ing capacity among the lectin pathway initiators [45].
Complement activation is one of the pathological
mechanisms contributing to ischemic/reperfusion injury
in ischemic stroke [2-4]. The selective ability for com-
plement activation after the binding of ficolin-3 to dying
cells may be responsible for the selective clinical correla-
tion with the levels of this protein. Further studies,
including simultaneous measurement of ficolin-3 levels
and of the generation of complement activation pro-
ducts, are necessary to confirm this assumption.
Our present findings also support previous data
[3,4,23], which showed that the lectin complement path-
way indeed plays an important role in the pathogenesis
of acute ischemic stroke; here we show that a ficolin-3-
dependent activation of the lectin pathway also contri-
butes to the pathological processes besides the pre-
viously suggested MBL-dependent activation.
Third, in accordance with the previous data [46-48]
a n de a r l i e rw o r kf r o mo u rg r o u p s[ 3 , 2 7 ] ,w em e a s u r e d
higher CRP levels in the sera of patients obtained at
Figure 4 Relationship between the baseline NIH score scale values and the 3-day serum S100b concentration with the outcome of the
disease in 65 patients with ischemic stroke. Panel A: Distribution of the patients with different outcome of the disease among patients with
low (< 6), medium (6-10) and high (> 10) baseline NIHSS scale. P value for c
2 test is indicated. Panel B: Differences in the S100b concentration
between patients with favorable (modified Rankin score: 0-2) and unfavorable modified Rankin score: 3-6) outcome.
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CRP levels measured on day 3 were strongly associated
with an unfavorable outcome of ischemic stroke. This
latter observation is in accordance with the recent find-
ings of Song et al. [29]. According to our present find-
ings, the clinical associations with the low ficolin-3 and
high CRP levels measured in the follow up samples are
independent, indicating that they reflect two different
pathways of inflammation contributing to the pathogen-
esis of the disease. These findings may have important
therapeutic implications. Anti-inflammatory drugs have
already been used for the treatment of ischemic stroke
with limited success. Since many pharmacological
agents, which are able to inhibit pathological comple-
ment activation are either approved for therapeutic pur-
poses (such as C1-inhibitor [49] or eculizimab [50]) or
are under clinical trials [51], these may be more effi-
ciently used for treatment of ischemic stroke either
alone or in combination with anti-inflammatory drugs.
The paper has some limitations. First of all, the num-
ber of patients tested is rather low and no late follow-up
samples were collected for ficolin measurements. Never-
theless our observations are novel and may initiate a
number of studies.
Conclusions
Our findings indicate that two seemingly different but
only partially identified pathways of neuroinflammation,
the ficolin-3-dependent activation of lectin pathway of
complement and CRP-dependent processes indepen-
dently contribute to the pathogenesis and poor outcome
of acute ischemic stroke. These findings may lead to the
introduction of novel treatment approaches for a disease
with a rather limited therapeutic arsenal at present.
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